Insights from 2025 ASCO® GI Annual Meeting
Video Player is loading.
10 seconds
Playback speed
ASCO® GI 2025 Insights: Trifluridine/Tipiracil vs. Placebo in Patients With Molecular Residual Disease Following Curative Resection of CRC - Ph3 ALTAIR Study
By
Insights from 2025 ASCO® GI Annual Meeting
FEATURING
Hideaki Bando
By
Insights from 2025 ASCO® GI Annual Meeting
FEATURING
Hideaki Bando
Comments 0
Login to view comments.
Click here to Login
